India, April 10 -- This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations, acquisitions, discontinuations, and positive data readouts spanning multiple therapeutic areas.
Let's dive into the details.
FDA and EU Approvals & Rejections
MacroGenics Resumes LINNET Study After FDA Lifts Partial Hold on Lorigerlimab Study
MacroGenics, Inc. (MGNX), announced that the FDA has lifted the partial hold on its Phase 2 LINNET study of Lorigerlimab in ovarian cancer and clear cell gynaecologic cancer. Enrollment will resume under a revised protocol with added safety measures, and the company expects a program update by mid-2026.
MGNX c...